Sandbox:Preeti: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 8: | Line 8: | ||
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Etiology | ||
! colspan="2" rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Mechanism | ! colspan="2" rowspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |Mechanism | ||
! colspan=" | ! colspan="11" rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical manifestations | ||
! colspan=" | ! colspan="8" align="center" style="background:#4479BA; color: #FFFFFF;" + |Paraclinical findings | ||
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard | ||
! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | ! rowspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | ||
|- | |- | ||
! colspan=" | ! colspan="8" align="center" style="background:#4479BA; color: #FFFFFF;" + |Lab findings | ||
|- | |- | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Demography | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |History | ||
! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms | ! colspan="4" align="center" style="background:#4479BA; color: #FFFFFF;" + |Symptoms | ||
! colspan=" | ! colspan="5" align="center" style="background:#4479BA; color: #FFFFFF;" + |Signs | ||
! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC | ! colspan="3" align="center" style="background:#4479BA; color: #FFFFFF;" + |CBC | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |PBS | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |PBS | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |PT/PTT | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |PT/PTT | ||
! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry | ! rowspan="2" align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry | ||
Line 38: | Line 36: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LAP | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |LAP | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC | ||
Line 44: | Line 41: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt | ||
|- | |- | ||
! colspan=" | ! colspan="27" align="left" style="background:#4479BA; color: #FFFFFF;" + |HL | ||
|- | |- | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ! align="center" style="background:#4479BA; color: #FFFFFF;" + | | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Hodgkin's Lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Hodgkin's Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 76: | Line 70: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
|- | |- | ||
! colspan=" | ! colspan="27" align="left" style="background:#4479BA; color: #FFFFFF;" + |NHL | ||
|- | |- | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |B Cell Lymphoma | ||
Line 82: | Line 76: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Precursor B-cell Lymphoma | * Precursor B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 117: | Line 108: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Second most common subtype of NHL | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
Line 131: | Line 123: | ||
* Central and peripheral lymphadenopathy | * Central and peripheral lymphadenopathy | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* [[Seizures]] | * [[Seizures]] | ||
Line 148: | Line 139: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Most common clinically indolent NHL | |||
|- | |- | ||
! | ! | ||
Line 173: | Line 163: | ||
| align="center" style="background:#F5F5F5;" + |Generalized lymphadenopathy | | align="center" style="background:#F5F5F5;" + |Generalized lymphadenopathy | ||
| align="center" style="background:#F5F5F5;" + | + | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Extranodal involvement of GI tract, lungs, and CNS | * Extranodal involvement of GI tract, lungs, and CNS | ||
Line 182: | Line 171: | ||
| align="center" style="background:#F5F5F5;" + |↓ | | align="center" style="background:#F5F5F5;" + |↓ | ||
| align="center" style="background:#F5F5F5;" + |Nl to ↓ | | align="center" style="background:#F5F5F5;" + |Nl to ↓ | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 193: | Line 181: | ||
* Nodular appearance | * Nodular appearance | ||
| align="center" style="background:#F5F5F5;" + |Elevated LDH | | align="center" style="background:#F5F5F5;" + |Elevated LDH | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 220: | Line 207: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Painless rapidly enlarging [[lymph nodes]] | * Painless rapidly enlarging [[lymph nodes]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 228: | Line 214: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* | * | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 242: | Line 227: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Hypergammaglobulinemia | * Hypergammaglobulinemia | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 261: | Line 245: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |LAP | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |LAP | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Hepatosplenomegaly | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |WBC | ||
Line 267: | Line 250: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Plt | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PBS | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |PBS | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT/PTT | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |PT/PTT | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Immunochemistry | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Histopathology | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other lab findings | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Other lab findings | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Gold standard | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Associated findings | ||
Line 301: | Line 282: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* [[Swollen lymph nodes]] in the neck, axilla, or groin | * [[Swollen lymph nodes]] in the neck, axilla, or groin | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* [[Ascites]] | * [[Ascites]] | ||
* [[Proptosis]] | * [[Proptosis]] | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 323: | Line 302: | ||
* [[basophilic]] cytoplasm | * [[basophilic]] cytoplasm | ||
* "Starry-sky pattern" | * "Starry-sky pattern" | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 332: | Line 310: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 364: | Line 339: | ||
| | | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 398: | Line 370: | ||
** Deletion 7q21-32 | ** Deletion 7q21-32 | ||
** Translocations of the CDK6 gene located on 7q21 | ** Translocations of the CDK6 gene located on 7q21 | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 426: | Line 396: | ||
* Epithelial histocytes | * Epithelial histocytes | ||
* Plasmacytic differentiation of neoplastic cells | * Plasmacytic differentiation of neoplastic cells | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 441: | Line 410: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + |+ | | align="center" style="background:#F5F5F5;" + | + | ||
| align="center" style="background:#F5F5F5;" + | | |||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 448: | Line 418: | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
* Hemorrhage | * Hemorrhage | ||
* Dyspepsia | * Dyspepsia | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 463: | Line 430: | ||
* Follicular cells in reactive zone | * Follicular cells in reactive zone | ||
* Centrocyte like cells in marginal zone lymphoma | * Centrocyte like cells in marginal zone lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 476: | Line 442: | ||
| align="left" style="background:#F5F5F5;" + | | | align="left" style="background:#F5F5F5;" + | | ||
* Mature B-cell Lymphoma | * Mature B-cell Lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 531: | Line 494: | ||
* [[Petechiae]] | * [[Petechiae]] | ||
* [[Splenomegaly]] | * [[Splenomegaly]] | ||
| | | | ||
| | | | ||
Line 541: | Line 503: | ||
** Decreased [[platelets]] count | ** Decreased [[platelets]] count | ||
** | ** | ||
| | | | ||
| | | | ||
Line 560: | Line 521: | ||
:* Central round [[nucleus]] | :* Central round [[nucleus]] | ||
:* Peri-nuclear clearing ("water-clear rim" appearance) | :* Peri-nuclear clearing ("water-clear rim" appearance) | ||
| | | | ||
| | | | ||
Line 568: | Line 528: | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Precursor T-cell lymphoblastic leukemia/lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Precursor T-cell lymphoblastic leukemia/lymphoma | ||
| | | | ||
* | * Precursor T-cell Lymphomas | ||
| | | | ||
| | | | ||
Line 599: | Line 556: | ||
| | | | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Adult T cell leukemia/lymphoma | ||
| | | | ||
| | | | ||
Line 629: | Line 583: | ||
|T cell lymphoma | |T cell lymphoma | ||
! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma | ! colspan="2" align="center" style="background:#DCDCDC;" + |Anaplastic large cell lymphoma | ||
| | | | ||
| | | | ||
Line 684: | Line 635: | ||
| | | | ||
* Cutaneous manifestations | * Cutaneous manifestations | ||
| | | | ||
| | | | ||
Line 704: | Line 652: | ||
! rowspan="6" align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma | ! rowspan="6" align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma | ||
! align="center" style="background:#DCDCDC;" + |Subcutaneous panniculitis-like T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Subcutaneous panniculitis-like T-cell lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 734: | Line 679: | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Hepatosplenic gamma-delta T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Hepatosplenic gamma-delta T-cell lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 764: | Line 706: | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Enteropathy-type intestinal T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Enteropathy-type intestinal T-cell lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 794: | Line 733: | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Extranodal T-cell lymphoma, nasal type | ! align="center" style="background:#DCDCDC;" + |Extranodal T-cell lymphoma, nasal type | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 824: | Line 760: | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Angioimmunoblastic T-cell lymphoma | ! align="center" style="background:#DCDCDC;" + |Angioimmunoblastic T-cell lymphoma | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
Line 854: | Line 787: | ||
| | | | ||
! align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma, unspecified | ! align="center" style="background:#DCDCDC;" + |Peripheral T-cell lymphoma, unspecified | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | | ||
| align="center" style="background:#F5F5F5;" + | | | align="center" style="background:#F5F5F5;" + | |
Revision as of 18:36, 7 January 2019
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Preeti Singh, M.B.B.S.[2]
Category | Disease | Etiology | Mechanism | Clinical manifestations | Paraclinical findings | Gold standard | Associated findings | |||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lab findings | ||||||||||||||||||||||||||
Demography | History | Symptoms | Signs | CBC | PBS | PT/PTT | Immunochemistry | Histopathology | Other | |||||||||||||||||
Inherited | Acquired | Constitutional symptoms | Rash | Abdominal pain | Diarrhea | V/S | Mass | LAP | Hepatosplenomegaly | Other | WBC | Hb | Plt | |||||||||||||
HL | ||||||||||||||||||||||||||
Hodgkin's Lymphoma | ||||||||||||||||||||||||||
NHL | ||||||||||||||||||||||||||
B Cell Lymphoma | Precursor B-cell lymphoblastic leukemia/lymphoma |
|
||||||||||||||||||||||||
Follicular lymphoma |
|
|
+ | + |
|
|
+ |
| ||||||||||||||||||
Mantle cell lymphoma |
|
|
Abdominal distention |
|
Generalized lymphadenopathy | + |
|
|
↓ | Nl to ↓ |
|
|
Elevated LDH | |||||||||||||
Diffuse large B cell lymphoma |
|
|
|
↓ | ↓ | Nl to ↓ |
|
Centroblastic
Immunoblastic
Anaplastic
|
|
|||||||||||||||||
Category | Disease | Etiology | Inherited | Acquired | Demography | History | Constitutional symptoms | Rash | Abdominal pain | Diarrhea | V/S | Mass | LAP | Hepatosplenomegaly | Other | WBC | Hb | Plt | PBS | PT/PTT | Immunochemistry | Histopathology | Other lab findings | Gold standard | Associated findings | |
Burkitt lymphoma |
|
|
|
|
|
|||||||||||||||||||||
B cell chronic lymphocytic leukemia/small lymphocytic lymphoma |
|
|||||||||||||||||||||||||
Marginal zone lymphoma | Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT) type |
|
||||||||||||||||||||||||
Splenic marginal zone lymphoma |
|
|
||||||||||||||||||||||||
Nodal marginal zone B-cell lymphoma |
|
+ |
|
|
|
| ||||||||||||||||||||
Lymphoplasmacytic lymphoma (Waldenstrom’s macroglobulinemia) |
|
|||||||||||||||||||||||||
Hairy cell leukemia |
|
|
|
|||||||||||||||||||||||
Precursor T-cell lymphoblastic leukemia/lymphoma |
|
|||||||||||||||||||||||||
Adult T cell leukemia/lymphoma | ||||||||||||||||||||||||||
T cell lymphoma | Anaplastic large cell lymphoma | |||||||||||||||||||||||||
Cutaneous T-cell lymphoma | Mycosis fungoides / Sézary syndrome |
|
|
|
||||||||||||||||||||||
Peripheral T-cell lymphoma | Subcutaneous panniculitis-like T-cell lymphoma | |||||||||||||||||||||||||
Hepatosplenic gamma-delta T-cell lymphoma | ||||||||||||||||||||||||||
Enteropathy-type intestinal T-cell lymphoma | ||||||||||||||||||||||||||
Extranodal T-cell lymphoma, nasal type | ||||||||||||||||||||||||||
Angioimmunoblastic T-cell lymphoma | ||||||||||||||||||||||||||
Peripheral T-cell lymphoma, unspecified |